Evidence map›Paper›PMID 28152001›Full record

ArticlePloS one2017

Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?

Annelieke Pasma, Charlotte Schenk, Reinier Timman, Adriaan van 't Spijker, Cathelijne Appels, Willemijn H van der Laan, Bart van den Bemt, Robert Goekoop, Johanna M W Hazes, Jan J V Busschbach

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Could a methotrexate blood assay improve adherence?Nature reviews. Rheumatology · 2019
    Article
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Annelieke PasmaDepartment of Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Charlotte SchenkDepartment of Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Reinier TimmanDepartment of Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Adriaan van 't SpijkerDepartment of Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Cathelijne AppelsDepartment of Rheumatology, Amphia hospital, Breda, the Netherlands.
Willemijn H van der LaanDepartment of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands.
Bart van den BemtDepartment of Pharmacy, Sint Maartenskliniek, Nijmegen, the Netherlands.
Robert GoekoopDepartment of Rheumatology, Haga hospital, the Hague, the Netherlands.
Johanna M W HazesDepartment of Rheumatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Jan J V BusschbachDepartment of Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Erasmus MC · NLSint Maartenskliniek · NLAmphia Ziekenhuis · NLHaga Hospital · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNon-adherence to disease-modifying antirheumatic drugs (DMARDs) is suspected to relate to health care costs. In this study we investigated this relation in the first year of treatment.

methodsIn a multi-center cohort study with a one year follow up, non-adherence was continuously measured using electronic monitored medication jars. Non-adherence was defined as the number of days with a negative difference between expected and observed opening of the container. Cost measurement focused on hospital costs in the first year: consultations, emergency room visits, hospitalization, medical procedures, imaging modalities, medication costs, and laboratory tests. Cost volumes were registered from patient medical files. We applied multivariate regression analyses for the association between non-adherence and costs, and other variables (age, sex, center, baseline disease activity, diagnosis, socioeconomic status, anxiety and depression) and costs.

resultsOf the 275 invited patients, 206 were willing to participate. 74.2% had rheumatoid arthritis, 20.9% had psoriatic arthritis and 4.9% undifferentiated arthritis. 23.7% of the patients were more than 20% non-adherent over the follow-up period. Mean costs are € 2117.25 (SD € 3020.32). Non-adherence was positively related to costs in addition to baseline anxiety.

conclusionNon-adherence is associated with health care costs in the first year of treatment for arthritis. This suggests that improving adherence is not only associated with better outcome, but also with savings.

Indexed as

Health Care CostsMedication AdherenceAdultAgedAntirheumatic AgentsArthritis, RheumatoidCohort StudiesDrug CostsFemaleHospital CostsHumansMaleMiddle AgedMultivariate AnalysisTime FactorsAntirheumatic Agents

Identifiers

PMID28152001
PMCPMC5289489
OpenAlexW2583609360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.